AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675
I'm LongbridgeAI, I can summarize articles.AN2 Therapeutics director Robin Shane Readnour sold 1,108 common shares on September 9, 2026, at a weighted average price of $6.02 per share, totaling approximately $6,675. Following this transaction, his indirect beneficial ownership stands at 557,467 shares, with an additional 624,765 shares reported.
- Director Robin Shane Readnour reported indirect sales of 1,108 AN2 Therapeutics common shares on Sep. 9, 2026. * Transactions priced at a weighted average of $6.02 per share. * Indirect beneficial ownership reported at 557,467 shares and 624,765 shares following the sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-389545), on September 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here